{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:32Z","timestamp":1740142412807,"version":"3.37.3"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background  Hepatorenal syndrome (HRS) is the most severe form of acute kidney injury in patients with advanced cirrhosis, and it is associated with high mortality. It is usually diagnosed according to criteria defined by the International Ascites Club. Currently, the most frequently indicated pharmacological therapy for the treatment of HRS is a combination of splanchnic vasoconstrictors (terlipressin or norepinephrine) in combination with albumin. With the progressive increase in healthcare spending, it is important to conduct a cost-effectiveness analysis of pharmacological treatment in patients who are diagnosed with HRS.  Objective: To perform a cost-effectiveness assessment for the use of terlipressin in combination with albumin to treat HRS in patients with cirrhosis.  Methods: Economic evaluation of cost-effectiveness based on secondary data from studies showed the efficacy of terlipressin therapy compared with norepinephrine combined with albumin or albumin alone. The cost-effectiveness analysis was calculated using an incremental cost-effectiveness ratio (ICER), and a sensitivity analysis was developed by varying the values of therapies and probabilities. The Brazilian real was the currency used in the analysis, and the results were converted to US dollars.  Results: After selection, eligibility, and evaluation of the quality of publications, the results demonstrated that administration of terlipressin or norepinephrine in combination with albumin in patients diagnosed with HRS type 1 was efficacious. The cost of treatment with terlipressin in combination with albumin was USD $1,644.06, administration of albumin alone was USD $912.02, and norepinephrine plus albumin was USD $2,310.78. Considering that the combination therapies demonstrated effectiveness, the incremental cost of terlipressin and norepinephrine in combination with albumin was USD $666.73, and an effectiveness of 0.570 was found for terlipressin in combination with albumin and 0.200 for norepinephrine in combination with albumin. The incremental effectiveness was 0.370, and the ICER was USD $1,801.97. Thus, the parameters of increasing cost per therapy and ICER indicated that the combined therapy of terlipressin plus albumin was cost effective compared to albumin alone or norepinephrine plus albumin in a public single-payer healthcare system.  Conclusion: A cost-effectiveness analysis showed that terlipressin in combination with albumin when administered concomitantly to patients who were diagnosed with type 1 HRS is cost-effective compared to norepinephrine in combination with albumin administered in a controlled environment.<\/jats:p>","DOI":"10.1590\/s0004-2803.202202000-48","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:26:47Z","timestamp":1657110407000},"page":"268-274","source":"Crossref","is-referenced-by-count":2,"title":["COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-1466","authenticated-orcid":false,"given":"Luciana Marcondes","family":"FERREIRA","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-1761","authenticated-orcid":false,"given":"D\u00e9bora Raquel","family":"TERRABUIO","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-8759","authenticated-orcid":false,"given":"Caroline Marcondes","family":"FERREIRA","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-2630","authenticated-orcid":false,"given":"Daniel Ferraz de Campos","family":"MAZO","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-9037","authenticated-orcid":false,"given":"Luciana Bertocco de Paiva","family":"HADDAD","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, Evaluation, and Management os Ascites, Spontaneous Bacterial Peritonitis and Hepatorrenal Syndrome: 2021 Practice Guidance by the American Association for the Study os Liver Diseases","volume":"74","author":"Biggins SW","year":"2021","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2013.03.039","article-title":"Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites","volume":"59","author":"Piano S","year":"2013","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clinre.2019.07.004","article-title":"Evolution of diagnostic criteria for acute kidney injury in patients with decompensated cirrhosis: a prospective study in a tertiary university hospital","volume":"44","author":"Vaz NF","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14218\/JCTH.2019.00060","article-title":"Incidence, mortality and predictors of acute kidney injury in patients with cirrhosis: a systematic review and meta-analysis","volume":"8","author":"Tariq R","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.01340406","article-title":"Hepatorenal syndrome: pathophysiology and management","volume":"1","author":"Wadei HM","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"Angeli P","year":"2019","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2215\/CJN.12451018","article-title":"Hepatorenal syndrome","volume":"14","author":"Francoz C","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10620-019-05858-2","article-title":"Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002-2018: a systematic review and meta-analysis","volume":"65","author":"Thomson MJ","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref9","first-page":"1","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar Jr AP","year":"2014","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11938-005-0030-z","article-title":"Hepatorenal syndrome","volume":"8","author":"Sandhu BS","year":"2005","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1345\/aph.1P195","article-title":"Terlipressin in hepatorenal syndrome","volume":"45","author":"Mazur JE","year":"2011","journal-title":"Ann Pharmacother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1572-0241.2005.40952.x","article-title":"Hepatorenal syndrome: a dreaded complication of end-stage liver disease","volume":"100","author":"C\u00e1rdenas A","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1055\/s-0040-100444","article-title":"Leberzirrhose und hepatorenales Syndrom: Das Ansprechen auf Terlipressin und Albumin ist mit besserem \u00dcberleben assoziiert [Response to terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome]","volume":"140","author":"Nguyen-Tat M","year":"2015","journal-title":"Dtsch Med Wochenschr"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin M","year":"2016","journal-title":"Hepatology"},{"issue":"69","key":"ref15","first-page":"24","article-title":"2018 clinical practice guidelines for the management of patients with descompensated cirrhosis","year":"2018","journal-title":"J Hepatol"},{"key":"ref16","first-page":"329","article-title":"Health technology assessment: II. Cost effectiveness analysis","volume":"47","author":"Secoli SR","year":"2010","journal-title":"Arq Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11605-012-2106-0","article-title":"A note on the Jadad score as an efficient tool for measuring trial quality","volume":"17","author":"Palys KE","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed M","year":"2008","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri S","year":"2008","journal-title":"Dig Dis Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure","volume":"71","author":"Arora V","year":"2020","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki P","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"Terlipressin study group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal AJ","year":"2008","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"REVERSE study investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer TD","year":"2016","journal-title":"Gastroenterology"},{"key":"ref24","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial","volume":"64","author":"Goyal O","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria C","year":"2007","journal-title":"J Hepatol"},{"key":"ref26","first-page":"474","article-title":"Hepatorenal syndrome: current concepts related to diagnosis and management","volume":"15","author":"Mattos \u00c1Z","year":"2016","journal-title":"Ann Hepatol."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso A","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s P","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref29","series-title":"Diretrizes metodol\u00f3gicas - diretriz de avalia\u00e7\u00e3o econ\u00f4mica","first-page":"1689","volume":"Vol. 1","year":"2015"},{"key":"ref30","first-page":"58","article-title":"Limiar de custo-efetividade: uma necessidade para o Brasil","volume":"8","author":"Trajman A","year":"2016","journal-title":"J Bras Econ da Sa\u00fade"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-28032016000200014","article-title":"Terlipressin versus noradrenaline for hepatorenal syndrome. Economic evaluation under the perspective of the Brazilian Public Health System","volume":"53","author":"Mattos \u00c2Z","year":"2016","journal-title":"Arq Gastroenterol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/S0168-8278(20)31920-6","article-title":"Continuous infusion of terlipressin for hepatorenal syndrome therapy: evaluation of efficacy and safety in real-life setting","volume":"73","author":"Linhares FS","year":"2020","journal-title":"J Hepatol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Custo efetividade do uso da terlipressina no tratamento da s\u00edndrome hepatorrenal"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032022000200268&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T13:31:57Z","timestamp":1658842317000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032022000200268&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["S0004-28032022000200268"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202202000-48","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}